Efficacy of Colestimide Coadministered With Atorvastatin in Japanese Patients With Heterozygous Familial Hypercholesterolemia (FH)

• Kawashiri Masa-aki

  Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Disease, Graduate School of Kanazawa University

• Higashikata Toshinori

  Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Disease, Graduate School of Kanazawa University

• Nohara Atsushi

  Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Disease, Graduate School of Kanazawa University

• Kobayashi Junji

  Department for Life-style-related Diseases, Graduate School of Kanazawa University

• Inazu Akihiro

  School of Health Science, Faculty of Medicine

• Koizumi Junji

  Department of General Medicine, Kanazawa University Hospital, Kanazawa University

• Mabuchi Hiroshi

  Molecular Genetics of Cardiovascular Disorders, Division of Cardiovascular Disease, Graduate School of Kanazawa University

抄録

Background Colestimide, a 2-methylimidazole-epichlorohydrin polymer, is a new bile-acid-sequestering resin, that is 4-fold as powerful at lowering low-density lipoprotein cholesterol (LDL-C) as the conventional resin (cholestyramine). Moreover, colestimide has excellent patient compliance because it is available in tablet form. Methods and Results The clinical efficacy of colestimide coadministered with atorvastatin on lipid and apolipoprotein concentrations was examined in 15 patients (M/F =10/5, mean ± SE age =54±9 years) with heterozygous familial hypercholesterolemia (FH). After a period of wash-out of any lipid-lowering drugs, atorvastatin (20-40 mg) was administered to patients for at least 8 weeks, and then 3 g of colestimide was administered for a further 8 weeks. Total and LDL-C significantly (<0.0001) decreased by 35% from 361 to 233 mg/dl and 41% from 274 to 161 mg/dl, respectively. Addition of colestimide caused a further significant 12% and 20% reduction, respectively, from the initial values to 205 and 129 mg/dl, respectively. Colestimide was also effective in reducing serum LDL-C concentrations in heterozygous FH patients with hypertriglyceridemia (triglycerides ≥150 mg/dl). Conclusions When monotherapy with atorvastatin is insufficient to treat severely hypercholesterolemic patients, such as those with heterozygous FH, colestimide acts to reinforce the action of statins. (Circ J 2005; 69: 515 - 520)<br>

収録刊行物

• Circulation Journal

  Circulation Journal 69 (5), 515-520, 2005

  一般社団法人 日本循環器学会

キーワード

• Atorvastatin
• Colestimide
• Familial hypercholesterolemia

詳細情報

• CRID: 1390282680081606144
• NII論文ID: 110002696133
• NII書誌ID: AA11591968
• DOI: 10.1253/circj.69.515
• ISSN: 13474820
• ISSN: 13469843
• ISSN: http://id.crossref.org/issn/13469843
• PubMed: 15849435
• Web Site: http://hdl.handle.net/2297/7212
• Web Site: http://www.jstage.jst.go.jp/article/circj/69/5/69_5_515/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/2006262506
• 本文言語コード: en
• データソース種別:
  • JaLC
  • IRDB
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可